5:57 PM
 | 
Oct 17, 2012
 |  BC Extra  |  Company News

Abbott forecasts financials for pharma split

Abbott Laboratories (NYSE:ABT) expects its AbbVie pharmaceutical spinout to record 2013 sales of more than $18 billion. R&D spending is expected to be about $2.5 billion, or 14% of sales. AbbVie is slated to start operations on Jan. 1 with a cash balance of about...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >